CN105111297A - 一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 - Google Patents
一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 Download PDFInfo
- Publication number
- CN105111297A CN105111297A CN201510502158.3A CN201510502158A CN105111297A CN 105111297 A CN105111297 A CN 105111297A CN 201510502158 A CN201510502158 A CN 201510502158A CN 105111297 A CN105111297 A CN 105111297A
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- imp1
- antigen
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 35
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 35
- 101000599778 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 title claims abstract description 30
- 101000988591 Homo sapiens Minor histocompatibility antigen H13 Proteins 0.000 title claims abstract description 30
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 title claims abstract description 29
- 239000000439 tumor marker Substances 0.000 title claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 title claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 238000013399 early diagnosis Methods 0.000 claims abstract description 9
- 238000004393 prognosis Methods 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 32
- 210000002381 plasma Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010010264 Condition aggravated Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- -1 nitrite ions Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
一种检测肝癌标志物IMP1抗原表位的氨基酸序列及应用,属于免疫学技术领域,本发明提供了一种肝癌相关基因IMP1的抗原氨基酸序列。应用IMP1多肽抗原检测肝癌患者血中相应的特异性自身抗体,这种自身抗体可作为肝癌标志物评估肝癌发生的危险度及预后疗效。这种抗原多肽及其抗体可用于制备肝癌早期诊断、预后预测试剂和开发治疗肝癌的靶向药物。
Description
技术领域
本发明属于生物技术领域,具体涉及一种具有检测肝癌标志物IMP1多肽片段。
背景技术
肝癌是目前我国发病率和致死率位居第二位的恶性肿瘤,每年约有30万例新发肝癌,占全球50%以上。肝癌发展迅速、易转移,是目前治疗最困难、预后最差的恶性肿瘤之一。然而,相对于乳腺癌、肺癌和前列腺癌等其他类型的恶性肿瘤,至今仍缺乏对肝癌发病相关肿瘤标志物分子认识。大量研究表明,血清或血浆中的肿瘤相关抗原能诱导机体产生自身抗体,在肿瘤患者血清中既存在肿瘤抗原,也存在针对该肿瘤抗原的自身抗体。因此,既可以利用抗体检测肿瘤抗原,也可以利用抗原检测肿瘤抗原的自身抗体,但利用肿瘤自身抗体检测肿瘤的特异性和敏感性均比利用肿瘤抗原检测肿瘤要高得多。很多肿瘤相关抗原不仅在肿瘤患者体内存在,在正常人体内也存在,因此检测肿瘤相关抗原作为诊断依据可信性差。而肿瘤自身抗体在正常人体内含量很低检测不到或根本不存在,若体内肿瘤自身抗体水平明显增高,则表明体内存在异常免疫情况,表明体内相关抗原水平发生波动,预示疾病的存在或原有疾病加重。
近年来的研究表明,在恶性肿瘤体积发展到可用现代影像学技术检出之前3-5年,患者血中可出现高浓度的肿瘤相关抗原自身抗体。因此,检测血中肿瘤相关抗原自身抗体具有预测肿瘤发病风险和早期诊断肿瘤的重要价值。是肿瘤临床诊断领域的重点发展方向之一。在国外已有诊断肺癌和乳腺癌的早期诊断试剂盒市售。然而,目前所报道的自身抗体检测方法敏感度低,特异性差,假阴性比率可高达50%以上。其主要原因是由于每一种肿瘤相关抗原自身抗体在癌症患者中的阳性检测率平均在10%左右。如何提高诊断试剂敏感度是当前需要亟待解决的关键问题。比较行之有效的方法是寻找新的可充当肿瘤标志物的自身抗体,然后与现有已知的肿瘤相关抗原自身抗体组合成具有敏感度高和特异性强的诊断试剂盒。
IMP1基因定位于11p13,包含10个外显子,48个氨基酸。IMP1和p62蛋白在氨基酸水平有大约66%到70%的同源性,属于同一mRNA结合蛋白家族。IMP1主要在早期胚胎发育阶段和妊娠中期表达,其与胰岛素样生长因子II(IGF-II)的不同转录物结合,参与调节IGF-IImRNA的定位、稳定、反转录及翻译,常常在许多肿瘤中过度表达,被认为是一种癌胚蛋白。IGF-II是一种包括67个氨基酸的单链多肽,IGF-II基因中含有四个启动子及九个外显子,其转录过程是由多个启动子调节每个启动子与不同的外显子非翻译调控区相关联,从而产生不同的转录产物。转录产物在胚胎期和成年期均特异性表达,其编码的IGF-II基因为一胚胎源性的生长因子,具有促进胚胎的发育及在细胞生长过程中促进细胞分裂增殖等作用。IGF-II转录异常参与了许多疾病及肿瘤的发生发展。许多研究表明,IMP1不仅与肿瘤的发生发展有关,而且与肿瘤的预后、转移有关,有望成为某些肿瘤的分子标记物及潜在的治疗靶点。基于IMP1在肿瘤组织和正常组织间表达的巨大差异和其在肿瘤发展中的重要作用,IMP1作为一个预测、预后指标和抗癌治疗靶点吸引了越来越多的关注。同时提示我们其在肝癌早期诊断的应用价值较好,以及作为潜在生物标志物的可能。
本发明通过自行设计的IMP1抗原表位多肽,检测肝癌患者血清及血浆中自身抗体表达水平并开发相应的试剂,预测肝癌发生的危险性,并为制备肝癌早期诊断及预后预测试剂盒奠定基础。
发明内容
本发明要解决的技术问题是公开一种检测肝癌标志物IMP1自身抗体的抗原表位序列。
本发明同时公开了IMP1抗原表位的用途。
本发明提供的一种检测肝癌标志物IMP1自身抗体的抗原表位氨基酸序列为:
H-PYGLIRGRIFFKIWPLSDFGFLRASPNGHRDC-OH
其纯度>95%,pH>7.0。
本发明所述的IMP1抗原表位多肽在制备肝癌早期诊断试剂盒中的应用。
本发明利用自行设计的IMP1蛋白的线性多肽,采用ELISA法检测肝癌患者血清及血浆中抗IMP1蛋白的特异性自身IgG抗体。自身IgG抗体水平升高表明肿瘤患者体内IMP1蛋白的表达量增加,预示患者可能出现原发性或继发性肝癌,可以预测肝癌发生与复发的危险性,指导临床医生对肝癌的早期诊断及预后预测。
抗原抗体的结合实际上只发生在抗原决定簇和抗体的抗原结合位点之间,两者在空间结构和空间构型上完全互补。因此抗原决定簇就可以代表整个蛋白与抗体结合的状态与亲和特性。另外,以重组蛋白为抗原,要经过载体构建、转染、表达、筛选、纯化等繁琐的过程,蛋白空间结构复杂,抗原表位不易暴露,因此抗原抗体结合的特异性差。此外,ELISA法的高灵敏性对纯化技术的稳定性要求极高,成本昂贵。
发明人遵循以下原则设计线性多肽抗原:①选择细胞膜蛋白表面区域;②选择不形成a-helix的序列;③两端的肽段比中间的排列合理;④避免蛋白内部重复;⑤避免同源性强的肽段;⑥序列中尽量避免Cys和Glu,不可以有太多的Pro,但有1-2个Pro利于肽链结构稳定,对产生特异性抗体有益。此外,该多肽抗原必须含有人类白细胞二类抗原(HLA)系统的限制性表位,包括HLA-DR,HLA-DPandHLA-DQ的限制性表位。这些表位可被90%以上华人群体的HLA二类抗原系统所识别。基于以上抗原设计原则及IMP1蛋白的生物学特性,本发明利用生物信息学和多个表位预测模拟软件,分析与抗原性相关的参数,设计了的线性氨基酸序列。IMP1线性多肽抗原由32个氨基酸残基组成,共含8个重叠表位,可检测至少8种单克隆抗体,具有高度的特异性。
ELISA法检测抗原表位
我们采用ELISA方法,对收集的血液进行检测,并得到各样本OD值进行分析。
质控各样本设双复孔,取平均OD值。OD值离散度判定:离散度=OD1-OD2/OD1+OD2,离散度≤0.1,为有效结果;离散度>0.1,为无效结果。取100份健康人血清等体积混合作为质控血(Qualitycontrol,QC),代表人群的普遍情况,每板均设2个QC血浆孔,以QC血浆孔的OD值变异水平判定结果的稳定性,批间变异CV=所有批次QC孔SD/所有批次QC孔OD均值<20%。批内变异CV=每日各板QC孔SD/每日各板QC孔均值<10%。
数据分析采用SPSS17.0forwindows进行统计学分析。采用特异结合指数(Specificbindingindex,SBI)来判定IMP1抗原多肽与血浆自身抗体的结合程度,SBI=IMP1OD值–NCOD值/QCOD值–NCOD值,NC为各样本的阴性对照。利用t检验分别比较恶性肝癌组与健康对照之间SBI值之间的差异,a=0.05。
ROC曲线是根据一系列不同的二分类方式(分界值或决定阈),以真阳性率(灵敏度)为纵坐标,假阳性率(1-特异度)为横坐标绘制的曲线。ROC曲线下的面积值在1.0和0.5之间。在AU>0.5的情况下,AU越接近于1,说明诊断准确度越好。ROC曲线将灵敏度与特异性以图示方法结合在一起,可准确反映某分析方法特异性和敏感性的关系,是试验准确性的综合代表。该发明采用Analyse-itforMicrosoftExcel软件绘制ROC曲线,计算曲线下面积(AU),判定灵敏度和特异度。
本发明应用IMP1抗原表位多肽检测到肝癌患者血清及血浆中的IMP1特异性自身IgG抗体,并且该反应具有高特异性和高灵敏性。
IMP1抗原表位多肽可用于制备肝癌早期诊断及预后预测试剂盒。
附图说明
图1为肝癌患者体抗IMP1自身IgG抗体水平的ROC曲线分析图(Diagonalsegmentareproducedbyties.)。
具体实施方式
下面结合具体实施例子,进一步阐述本发明。应理解,这些实施例子仅用于说明本发明而不用于限制本发明的范围。
实施例1
试剂盒制备
1试剂试剂配制见Tab.2~7。
2操作
(1)包被:酶标板应用洗涤缓冲液清洗3遍,工作抗原用包被液稀释至工作浓度,包被于酶标板,4℃过夜。
(2)加谷氨酸:洗涤缓冲液清洗3遍,用包被液稀释谷氨酸至浓度100μg/ml,每孔200μl,37℃或室温孵育1h;
(3)加血浆和质控对照(一抗):酶标板应用洗涤缓冲液清洗3遍,利用包被液将血浆稀释至合适浓度,一般为1:100~1:500,每孔100μl,37℃或室温孵育1h;
(4)二抗孵育:洗涤缓冲液清洗3遍,利用包被液稀释二抗标准液IgG,工作浓度1:20000,每孔加100μl,37℃或室温孵育1h;
(5)显色:洗涤缓冲液清洗3遍,每孔加100μl底物显色液,室温避光30~45min。
(6)检测:每孔加50μl终止液,10min内检测,检测波长为450nm,参考波长为630nm。
实施例2
肝癌患者的IMP1自身IgG抗体检测
1样本收集:本研究从吉林大学第三医院、省肿瘤医院选取经放射学检查和组织学检查确诊肝癌样本103例。所有血清样本采集前未经过任何抗癌治疗,并具有全面的临床资料和信息。同时招募了健康对照组样本121例。临床访谈及影像学检查均排除肝癌患病可能。健康组与肝癌组在性别、年龄匹配,具有可比性(P>0.05)
2检测结果:IMP1的自身抗体表达水平(Tab.8):肝癌组与健康对照组相比存在统计学差异(Z=-5.167,P<0.001)。
ROC曲线分析:肝癌患者IMP1自身IgG抗体检测在ROC曲线下面积为0.723(SE=0.030,95%CI:0.568-0.695)(图1和Tab.9)。
以上数据充分表明,利用本发明所设计的抗原表位多肽检测得到的肝癌患者自身抗体IgG水平与正常健康组比较有显著性统计学差异。
Tab.8抗IMP1自身IgG抗体在肝癌患者和健康对照样本中的表达水平
Antibody a | Mean±SD(n) | Z | P |
control | 1.054±0.22 (121) | ||
malignant | 1.378±0.21 (103) | -5.167 | 0.000 |
Tab.9肝癌中抗IMP1自身IgG抗体的ROC曲线分析
Antibody | AUC | SE a | 95%CI | Sensitivity (%) | Specificity (%) |
malignant | 0.725 | 0.030 | 0.568-0.695 | 20.8 | 90 |
H-PYGLIRGRIFFKIWPLSDFGFLRASPNGHRDC-OH
其纯度>95%,pH>7.0。
Claims (2)
1.一种检测肝癌标志物IMP1抗原表位多肽,其特征在于:氨基酸序列为
H-PYGLIRGRIFFKIWPLSDFGFLRASPNGHRDC-OH
其纯度>95%,pH>7.0。
2.根据权利要求1所述的检测肝癌标志物IMP1抗原表位多肽在制备肝癌早期诊断及预后预测试剂盒的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510502158.3A CN105111297B (zh) | 2015-08-17 | 2015-08-17 | 一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510502158.3A CN105111297B (zh) | 2015-08-17 | 2015-08-17 | 一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105111297A true CN105111297A (zh) | 2015-12-02 |
CN105111297B CN105111297B (zh) | 2017-08-29 |
Family
ID=54659443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510502158.3A Expired - Fee Related CN105111297B (zh) | 2015-08-17 | 2015-08-17 | 一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105111297B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017209396A1 (ko) * | 2016-05-30 | 2017-12-07 | 가톨릭대학교 산학협력단 | 간암의 진단 및 예후 예측용 바이오 마커 및 그의 용도 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103293308B (zh) * | 2013-05-24 | 2014-11-26 | 尉军 | 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用 |
-
2015
- 2015-08-17 CN CN201510502158.3A patent/CN105111297B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103293308B (zh) * | 2013-05-24 | 2014-11-26 | 尉军 | 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用 |
Non-Patent Citations (1)
Title |
---|
AUTHOR UNKNOW: "NCBI:XP_012307688.1", 《NCBI> * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017209396A1 (ko) * | 2016-05-30 | 2017-12-07 | 가톨릭대학교 산학협력단 | 간암의 진단 및 예후 예측용 바이오 마커 및 그의 용도 |
US11180814B2 (en) | 2016-05-30 | 2021-11-23 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Biomarker for diagnosis and prognosis prediction of liver cancer, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105111297B (zh) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102209899B (zh) | 作为癌症的标记物的pacap | |
CN101652484B (zh) | 前列腺癌标志物spink1及其应用 | |
CN103293308B (zh) | 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用 | |
CN102504027B (zh) | 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用 | |
CN102432683B (zh) | 一种多表位tk1抗体的制备及其在肿瘤患者早期复发风险及预后评估中的应用 | |
CN103403550B (zh) | 使用与braf v600e特异性结合的抗体诊断癌症的工具和方法 | |
CN102603892B (zh) | 一种肿瘤标志物foxp3抗原多肽及应用 | |
CN104277102A (zh) | 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用 | |
CN102516390A (zh) | 一种多表位tk1抗体的制备及其在评估肿瘤患者治疗效果中的应用 | |
CN103207277A (zh) | 一种人源性可溶型cd74蛋白的elisa检测试剂盒及检测方法 | |
CN105037534B (zh) | 一种检测肺癌标志物myc抗原表位氨基酸序列及应用 | |
CN104262467B (zh) | 一种检测乳腺癌标志物epr-1抗原表位氨基酸序列及应用 | |
CN105111297A (zh) | 一种检测肝癌标志物imp1抗原表位氨基酸序列及应用 | |
CN104558147B (zh) | 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用 | |
US20150377889A1 (en) | Galectin-3 as a marker for prostate cancer | |
CN105017405B (zh) | 一种检测肝癌标志物bmi1抗原表位氨基酸序列及应用 | |
CN105017404A (zh) | 一种检测肝癌标志物ezh2抗原表位氨基酸序列及应用 | |
CN105218656A (zh) | 一种检测宫颈癌标志物Survivin抗原表位氨基酸序列及应用 | |
CN108152496B (zh) | Mest蛋白在制备肺癌辅助诊断和/或预后判断的试剂盒中的应用 | |
CN104422763A (zh) | 抗原组在制备诊断疾病的试剂盒中的用途和试剂盒 | |
CN102532298B (zh) | 与自身抗体特异性结合的abcc3抗原多肽及应用 | |
Wu et al. | Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53-and phage-ELISA: correlation to clinical parameters | |
CN104892746B (zh) | 一种检测宫颈癌标志物-foxp3自身抗体表位氨基酸序列及应用 | |
CN102358754B (zh) | 源自rhbdd1的蛋白及其在制备用于检测结直肠癌或乳腺癌的单克隆抗体中的用途 | |
CN104945496A (zh) | 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170721 Address after: 130012 Changchun Qianjin Street, Jilin, No. 2699 Applicant after: Jilin University Address before: 130031 room 19, building 406, family of water people, Changchun, Jilin Applicant before: Sun Shilong |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170829 Termination date: 20200817 |
|
CF01 | Termination of patent right due to non-payment of annual fee |